CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Posted on December 3, 2020
Categories: ET Treatment, In the News
Hi
I was diagnosed with ET in my 20 my tremor is affecting my every day living. Medication is not helping. Would there be any trials that are suitable. I am in my late 30.
Sincerely yours,
Jessica Katan
Hi Jessica. We have a number of clinical trials listed on our website: https://essentialtremor.org/what-we-do/research/research-recruitment/. Another good resource for you is clinicaltrials.gov. Just key in “essential tremor” under “condition” to see what’s currently happening in the area of research. Thank you for your interest in participating in a clinical trial.